Form 8-K - Current report:
SEC Accession No. 0000950170-25-060563
Filing Date
2025-04-30
Accepted
2025-04-30 07:01:42
Documents
13
Period of Report
2025-04-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20250430.htm   iXBRL 8-K 46008
2 EX-99.1 lrmr-ex99_1.htm EX-99.1 144469
3 GRAPHIC img46574298_0.jpg GRAPHIC 282533
  Complete submission text file 0000950170-25-060563.txt   678284

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20250430.xsd EX-101.SCH 23893
15 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20250430_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 25890880
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)